Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy |
| |
Authors: | Howell Kobporn L DeVita Robert J Garcia-Calvo Margarita Meurer Roger D Lisnock JeanMarie Bull Herbert G McMasters Daniel R McCann Margaret E Mills Sander G |
| |
Affiliation: | Department of Medicinal Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA. kobporn_howell@merck.com |
| |
Abstract: | Ezetimibe (Zetia®), a cholesterol-absorption inhibitor (CAI) approved by the FDA for the treatment of hypercholesterolemia, is believed to target the intestine protein Niemann-Pick C1-Like 1 (NPC1L1) or its pathway. A spiroimidazolidinone NPC1L1 inhibitor identified by virtual screening showed moderate binding activity but was not efficacious in an in vivo rodent model of cholesterol absorption. Synthesis of analogs established the structure–activity relationships for binding activity, and resulted in compounds with in vivo efficacy, including 24, which inhibited plasma cholesterol absorption by 67% in the mouse, thereby providing proof-of-concept that non-β-lactams can be effective CAIs. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|